This review assessed medical care for hepatitis C virus infected methadone maintenance patients, concluding that there was support for antiviral therapy in methadone maintenance patients with hepatitis C virus infection. However, given the lack of reporting of the review process and the paucity of good quality studies, the results should be treated with caution.
Data extraction
Data on the proportions of patients with sustained virological response, completing antiviral therapy and required changes in methadone dose were extracted.
The authors stated neither how the data were extracted for review nor how many reviewers performed the data extraction.
Methods of synthesis
Studies were combined in a narrative synthesis with study differences evident from the tabulated data.
Results of the review
Six studies were included in the treatment of hepatitis C virus infection (n=206 on methadone and n=162 in the contrast group). Five studies included inclusion and exclusion criteria and one partially so. Five of the studies used an intentionto-treat analysis. Four studies reported withdrawals and dropouts adequately, one partially and one had no drop outs.
The rates of sustained virological response in maintenance patients ranged from 28 per cent to 94 per cent. Completion rates ranged from 50 per cent to 100 per cent. There was no significant difference in the rates of sustained virological response or psychiatric side-effects in methadone maintenance patients compared with contrast groups. A brief narrative of liver transplantation results was presented.
